Model Medicines

Model Medicines, founded in 2019, is an AI-driven, human health company dedicated to utilizing AI to model all of chemistry and human biology in order to expedite the development of life-changing drugs. With a focus on AI-drug discovery, the company has already amassed an impressive portfolio of 182 compounds for 26 targets. Their robust pipeline includes patent-pending therapeutics for a wide array of health concerns such as oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. Based in La Jolla, CA, the company recently secured a notable $4.10M Seed Round investment on 01 February 2021, with participation from influential investors including Nex Cubed, 8VC, Irving Investors, Triton Funds, Particle Accelerator Limited (ParticleX), Carter Comstock, and Friedman BioVentures. Model Medicines' pioneering approach positions it at the forefront of the biotechnology and pharmaceutical industries, offering promising prospects for innovative drug development propelled by AI technology. This startup holds substantial potential for groundbreaking contributions to the healthcare landscape.